A carregar...
CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers
Although imatinib mesylate has been a major breakthrough in the treatment of advanced GIST, complete responses are rare and most patients eventually develop resistance to the drug. Thus the possibility of an imatinib-insensitive cell subpopulation within GIST tumors, harboring stem cell characterist...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3366284/ https://ncbi.nlm.nih.gov/pubmed/22076958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/gcc.20942 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|